The cost of medications for in vitro fertilization (IVF) has skyrocketed by 84% over the past decade, significantly outpacing the 37% average increase seen across all prescription drugs, as reported by the GoodRx List Price Index. This surge in medication costs contributes to the already substantial financial burden of IVF, rendering the treatment increasingly unaffordable for many.
The report detailed several medications commonly used in IVF, including clomiphene, Ganirelix, Gonal-F, Follistim AQ, Leuprolide, Menopur, and Ovidrel, among others. The high cost of these medications can be attributed to their complexity as biologics, which are expensive to manufacture, as well as their status as patented brand-name drugs that limit access to more affordable generic options.
Patients face considerable financial hurdles, as a single IVF cycle can cost between $15,000 and $30,000, with medications often making up a significant portion of that expense—costs that insurance frequently does not cover. For those who do qualify for coverage, additional barriers such as specific hormone level requirements or necessary fertility assessments by doctors can complicate access. Moreover, state-level variations in coverage and definitions of infertility add to the challenges.
While the medications required for IVF vary from patient to patient, they are crucial for the egg retrieval process. Unfortunately, repeated unsuccessful IVF attempts can deepen the financial strain associated with these treatments, making them unattainable for many, particularly individuals from lower socioeconomic backgrounds. Infertility impacts approximately 1 in 6 people of reproductive age globally, according to the World Health Organization.
The financial stress linked to IVF can also intensify psychological distress. Research from the National Bureau of Economic Research indicates that infertility can lead to significant mental health issues, including feelings of guilt, inadequacy, and an increased risk of divorce. The combination of financial burdens and emotional challenges can greatly diminish a patient’s overall quality of life.
In response to these mounting challenges, advocates are pushing for enhanced public funding and stronger legislative support to improve access to IVF. However, the subject remains contentious. In June 2024, Senate Republicans voted against the “Right to IVF” act, which aimed to ensure nationwide access to IVF and other fertility treatments while expanding insurance coverage. Additionally, a ruling from the Alabama Supreme Court equating IVF embryos to children has encouraged at least 14 other states to consider similar restrictions.
Despite these challenges, approximately 2% of babies born in the U.S. each year are conceived through IVF. Adjustments in policies aimed at reducing the cost of IVF medications could significantly enhance access and mitigate disparities in fertility treatment availability.
“Millions of individuals encounter catastrophic healthcare expenses when seeking infertility treatment, which underscores a major equity issue and often traps those affected in medical poverty,” stated Pascale Allotey, director of sexual and reproductive health and research at WHO. “Improved policies and public financing can greatly enhance access to treatment and safeguard poorer households from falling into poverty due to these costs.”
Related topics:
